Overview of Dr. Sarva
Dr. Harini Sarva is a neurologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, New York-Presbyterian Hospital, and Long Island Jewish Medical Center. She received her medical degree from State University of New York Downstate Medical Center College of Medicine and has been in practice 13 years. She is one of 474 doctors at New York-Presbyterian Hospital and one of 109 doctors at Long Island Jewish Medical Center who specialize in Neurology. She has more than 60 publications and over 500 citings.
Office
428 E 72nd St
Ofc 400
New York, NY 10021Fax+1 212-746-8296
Education & Training
SUNY Downstate Health Sciences UniversityResidency, Neurology, 2008 - 2012
State University of New York Downstate Medical Center College of MedicineClass of 2004
Certifications & Licensure
NY State Medical License 2011 - 2026
NJ State Medical License 2020 - 2023
American Board of Psychiatry and Neurology Neurology
Clinical Trials
- A Double-blind Study to Evaluate the Safety of Glutamic Acid Decarboxylase Gene Transfer in Parkinson's Participants Start of enrollment: 2022 Oct 05
Roles: Principal Investigator
Publications & Presentations
PubMed
- Adult-Onset Myoclonus in a Large Urban Inpatient Setting: A Retrospective Cohort Study.Karin Oh, Moath Hamed, Donna Zarandi, Moyosore Oluleye, Anas Zaher
Tremor and Other Hyperkinetic Movements. 2025-01-01 - 4 citationsSafety and Efficacy of Staged, Bilateral Focused Ultrasound Thalamotomy in Essential Tremor: An Open-Label Clinical Trial.Michael G Kaplitt, Vibhor Krishna, Howard M Eisenberg, W Jeffrey Elias, Pejman Ghanouni
JAMA Neurology. 2024-09-01 - 1 citationsDiagnostic Criteria for Primary Tic Disorders: Time for Reappraisal.Marianna Sarchioto, Jessica Frey, Christos Ganos, Donald L Gilbert, Andreas Hartmann
Movement Disorders. 2024-08-01
Press Mentions
BlueRock Therapeutics to Incorporate Wearable and Invisible Contactless Digital Health Technologies from Rune Labs and Emerald Innovations in Parkinson’s Disease Clinical TrialMarch 14th, 2023- BlueRock Therapeutics Announces Completion of Enrollment of Phase 1 Trial in Patients with Parkinson's DiseaseMay 31st, 2022
Grant Support
- Clinical Research Sites for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT sites) (U24 Clinical Trial Not Allowed)COLUMBIA UNIVERSITY HEALTH SCIENCES2018–2028
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
